CD274 and breast carcinoma: In gBRCA-mutant breast cancer, while the durvalumab + olaparib combination seemed promising in the MEDIOLA trial, with a 80% DCR at 12 weeks [276], results of the randomized phase II trial comparing anti-PD-L1 atezolizumab plus olaparib versus olaparib monotherapy showed no significant difference in PFS or overall survival [288].